2024
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer
McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology 2024, 183: 133-140. PMID: 38493021, DOI: 10.1016/j.ygyno.2024.01.028.Peer-Reviewed Original ResearchLow grade serous ovarian carcinomaWhole-exome-sequencingGain-of-function mutationsVS-4718Preclinical efficacyLow grade serous ovarian cancerSerous ovarian cancerControl-treated miceTumor growth inhibitionWild-type KRASLoss of heterozygosityDecreased p-ERKRAF/MEK inhibitionMedian survivalOvarian cancerRecurrence rateTherapeutic optionsOral gavageTumor growthTumor samplesIn vivo activityMAPK pathway genesRAF/MEK inhibitorsP-ERKEx vivo
2022
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor
Tymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. Gynecologic Oncology 2022, 166: 117-125. PMID: 35599167, DOI: 10.1016/j.ygyno.2022.05.005.Peer-Reviewed Original ResearchConceptsUterine carcinosarcomaCS cell linesSignature 3Cell linesPolymerase inhibitorsOverall animal survivalFresh tumor samplesPoly (ADP-ribose) polymerase (PARP) inhibitorsXenograft tumor growthG2/M phaseAggressive malignancyCS patientsPrimary tumorCell cycle arrestPrimary cell linesPoor survivalClinical studiesPreclinical sensitivityCarcinosarcomaTumor growthAnimal survivalOlaparib activityTumor samplesOlaparibAntitumor activity
2008
Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells
Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T, Mor G. Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells. Oncogene 2008, 27: 4712-4723. PMID: 18408758, PMCID: PMC3041589, DOI: 10.1038/onc.2008.112.Peer-Reviewed Original ResearchConceptsOvarian cancer cellsEOC cellsTumor samplesNuclear factor-κB activationCancer cellsOvarian cancer ascitesChemoresistant ovarian cancerNF-κB pathwayNF-κB activityPatient tumor samplesIKKβ pathwayTLR-MyD88Chronic inflammationEffective therapyCancer ascitesOvarian cancerInflammatory microenvironmentIKKβ expressionSolid tumorsTumor progressionCancer progressionIκB kinaseAbnormal formsMicroRNA hsaTissue repair
1984
Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro.
Lazo JS, Schwartz PE, MacLusky NJ, Labaree DC, Eisenfeld AJ. Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro. Cancer Research 1984, 44: 2265-71. PMID: 6722767.Peer-Reviewed Original ResearchConceptsEstrogen receptorFmol/Tumor samplesMicroM tamoxifenOvarian tumorsOvarian carcinomaColony formationAntiproliferative actionAntiproliferative effectsERc contentHuman epithelial ovarian tumorsSolid ovarian carcinomasERc levelsProgestin receptor levelsEpithelial ovarian tumorsDirect antiproliferative actionCombination of doxorubicinCytosolic estrogen receptorHuman ovarian carcinomaSoft agarMaximum antiproliferative effectsPRC contentsPRc levelsReceptor levelsTamoxifen